Find out about top-line trial data, approval decisions, advisory panel meetings and more in advance of others.
The outcomes of these events dramatically impact the competitive landscape of late-stage drug development and impact the stock prices of many market players, especially smaller companies. Therefore, the sooner you know about them, the better.
Discover the catalysts from 23 drugs, devices and diagnostics expected to occur in Q4 2016. Learn each drug’s likelihood of Phase/PDUFA review success and overall Likelihood of Approval (LOA) given their particular phase, drug class, and disease group.
Indications covered are:
• Alzheimer’s Disease (AD)
• Bladder Cancer
• Community Acquired Pneumonia (CAP) (Antibacterial)
• Congestive Heart Failure (CHF) and Cardiomyopathies
• Crohn’s Disease
• Diabetes Mellitus, Type I
• Diabetes Mellitus, Type II
• Dyslipidemia / Hypercholesterolemia
• Friedreich’s Ataxia
• Hepatitis B (HBV) Treatment (Antiviral)
• Hepatitis B Prevention (Vaccines, Antiviral)
• Immune Thrombocytopenic Purpura (ITP)
• Irritable Bowel Syndrome (IBS)
• Ischemic Stroke
• Moderate to Severe Pain
• Multiple Sclerosis (MS)
• Neuroendocrine Tumors (NET)
• Non-Small Cell Lung Cancer (NSCLC)
• Peripheral Arterial Disease (PAD)
• Rheumatoid Arthritis (RA)